Cdk9 | cyclin-dependent kinase 9 inhibitor | CAS#1415559-43-1

MedKoo Cat#: 128319 | Name: Cdk9 Inhibitor

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cdk9 inhibitor is an inhibitor of cyclin-dependent kinase 9.

Chemical Structure

Cdk9 Inhibitor

CAS#1415559-43-1

Theoretical Analysis

MedKoo Cat#: 128319

Name: Cdk9 Inhibitor

CAS#: 1415559-43-1

Chemical Formula: C26H21N5O4S

Exact Mass: 499.1314

Molecular Weight: 499.55

Elemental Analysis: C, 62.51; H, 4.24; N, 14.02; O, 12.81; S, 6.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Cdk9 Inhibitor; Cdk-9 Inhibitor; Cdk 9 Inhibitor; Cdk9-IN-1; Cyclin-dependent Kinase 9 Inhibitor; Cyclin-dependent Kinase 9 Inhibitor-1; Cyclin-dependent Kinase 9-IN-1; Cdk9 Inhibitor 1; KIN001-270

IUPAC/Chemical Name

N-(5-((6-(3-(1,3-dioxoisoindolin-2-yl)phenyl)pyrimidin-4-yl)amino)-2-methylphenyl)methanesulfonamide

InChi Key

CKUFOBCNTCLXJP-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H21N5O4S/c1-16-10-11-18(13-22(16)30-36(2,34)35)29-24-14-23(27-15-28-24)17-6-5-7-19(12-17)31-25(32)20-8-3-4-9-21(20)26(31)33/h3-15,30H,1-2H3,(H,27,28,29)

SMILES Code

CC1=CC=C(NC2=NC=NC(C3=CC(N4C(C(C=CC=C5)=C5C4=O)=O)=CC=C3)=C2)C=C1NS(C)(=O)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 499.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Soosainathan A, Iravani M, El-Botty R, Alexander J, Sourd L, Morisset L, Painsec P, Orha R, Nikitorowicz-Buniak J, Pancholi S, Haider S, Dowsett M, Marangoni E, Martin LA, Isacke CM. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers. Cancer Res. 2024 Jan 2;84(1):17-25. doi: 10.1158/0008-5472.CAN-23-0650. PMID: 37801608; PMCID: PMC10758688. 2: Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, Pop- Damkov P, Su N, Roamio Franklin VN, Sekhar Reddy Chilamakuri C, D'Santos CS, Shao W, Saeh JC, Koch R, Weinstock DM, Zinda M, Fawell SE, Drew L. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. Clin Cancer Res. 2020 Feb 15;26(4):922-934. doi: 10.1158/1078-0432.CCR-19-1853. Epub 2019 Nov 7. PMID: 31699827. 3: Kuang Z, Guo K, Cao Y, Jiang M, Wang C, Wu Q, Hu G, Ao M, Huang M, Qin J, Zhao T, Lu S, Sun C, Li M, Wu T, Liu W, Fang M. The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma. Br J Cancer. 2023 Dec;129(12):1915-1929. doi: 10.1038/s41416-023-02464-y. Epub 2023 Oct 26. PMID: 37884683; PMCID: PMC10703862. 4: Zhang H, Huang C, Gordon J, Yu S, Morton G, Childers W, Abou-Gharbia M, Zhang Y, Jelinek J, Issa JJ. MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer. Clin Epigenetics. 2024 Jan 3;16(1):3. doi: 10.1186/s13148-023-01617-3. PMID: 38172923; PMCID: PMC10765884. 5: Jiang V, Lee W, Zhang T, Jordan A, Yan F, Cai Q, McIntosh J, Vargas J, Liu Y, Wang M. The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma. Biomark Res. 2024 Jun 18;12(1):62. doi: 10.1186/s40364-024-00589-7. PMID: 38886769; PMCID: PMC11184686. 6: Kato N, Kozako T, Ohsugi T, Uchida Y, Yoshimitsu M, Ishitsuka K, Aikawa A, Honda SI. CDK9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth in Adult T-Cell Leukemia/Lymphoma. Biol Pharm Bull. 2023;46(9):1269-1276. doi: 10.1248/bpb.b23-00228. PMID: 37661406. 7: Zhong Y, Xu J, Ding S, Cao H, Zhang Y, Hu B, Han S, Yang H, Cheng M, Li J, Sun Y, Liu Y. Discovery of novel CDK9 inhibitor with tridentate ligand: Design, synthesis and biological evaluation. Bioorg Chem. 2024 Sep;150:107550. doi: 10.1016/j.bioorg.2024.107550. Epub 2024 Jun 10. PMID: 38878756. 8: Zhao F, Wang Y, Zuo H, Ru Y, Wang Y. Cyclin-Dependent kinase 9 (CDK9) inhibitor Atuveciclib ameliorates Imiquimod-Induced Psoriasis-Like dermatitis in mice by inhibiting various inflammation factors via STAT3 signaling pathway. Int Immunopharmacol. 2024 Mar 10;129:111652. doi: 10.1016/j.intimp.2024.111652. Epub 2024 Feb 8. PMID: 38335657. 9: Zhong Y, Xu J, Zhou R, Tang L, Ding S, Ren Z, Song N, Hu B, Yang H, Sun Y, Cheng M, Li J, Liu Y. Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation. J Med Chem. 2024 Mar 28;67(6):4739-4756. doi: 10.1021/acs.jmedchem.3c02329. Epub 2024 Mar 15. PMID: 38488882. 10: Sakamoto T, Ajiro M, Watanabe A, Matsushima S, Ueda K, Hagiwara M. Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy. BMC Cancer. 2023 Jan 20;23(1):71. doi: 10.1186/s12885-023-10540-y. PMID: 36670405; PMCID: PMC9862866.